Teva Pharmaceutical Industries Limited (NYSE:TEVA) finished Thursday with a subtraction of -$0.07 to close at $9.67, a downside of -0.72 percent. An average of 6,634,660 shares of common stock have been traded in the last five days. There was a gain of $0.16 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 9,808,445 shares traded, while the 50-day average volume stands at 10,625,939.
TEVA stock has increased by 13.50% in the last month. The company shares reached their 1-month lowest point of $8.21 on 08/01/23. With the stock rallying to its 52-week high on 01/12/23, shares of the company touched a low of $7.09 and a high of $11.44 in 52 weeks. It has reached a new high 5 times so far this year and achieved 6.03% or $0.55 in price. In spite of this, the price is down -15.51% from the 52-week high.
Insider Transactions
TEVA stock investors should be aware that Teva Pharmaceutical Industries Limited (TEVA) stock had its last reported insider trading activity 18 days ago on Aug 07. In this transaction, the insider spent $341,889. Chief Accounting Officer, Weiss Amir, disposed of 1,981 shares at a price of $9.92 on Aug 04. The insider now owns more than $19,658 worth of shares. Prior to that, Hughes Eric A went on to Sale 52,742 shares at $8.30 each on Aug 01. An amount of $437,690 was transacted.
Valuation Metrics
Teva Pharmaceutical Industries Limited (TEVA) stock’s beta is 1.15. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.72, the price-to-book (PB) ratio at 1.53, and the price-to-cash flow ratio at 9.17.
Financial Health
The quick ratio of Teva Pharmaceutical Industries Limited for the three months ended June 29 was 0.70, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.65 and a total debt to equity ratio of 2.93 for the quarter ending June 29. Teva Pharmaceutical Industries Limited’s EBITDA margin for the year ending June 29 is 26.73%, while its operating margin for the same period stands at -7.20%. Its gross profit as reported stood at $6.97 billion compared to revenue of $14.93 billion.
Earnings Surprise
For the three-month period that ended June 29, Teva Pharmaceutical Industries Limited had $18.7 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$863.0 million in the quarter, while revenues were grew 73.12%. The analyst consensus anticipated Teva Pharmaceutical Industries Limited’s latest quarter earnings to come in at $0.52 per share, but it turned out to be $0.56, a 7.70% surprise. For the quarter, EBITDA amounted to -$346.0 million. Shareholders own equity worth $1.12 billion.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Teva Pharmaceutical Industries Limited (TEVA) price momentum. RSI 9-day as of the close on 24 August was 62.49%, suggesting the stock is Neutral, with historical volatility in this time frame at 19.72%.
As of today, TEVA’s price is $9.67 +1.68% or $0.16 from its 5-day moving average. TEVA is currently trading +14.85% higher than its 20-day SMA and +9.27% higher than its 100-day SMA. However, the stock’s current price level is +28.42% above the SMA50 and +14.17% above the SMA200.
The stochastic %K and %D were 67.80% and 70.07%, respectively, and the average true range (ATR) was 0.25. With the 14-day stochastic at 63.38% and the average true range at 0.26, the RSI (14) stands at 64.16%. The stock has reached 0.13 on the 9-day MACD Oscillator while the 14-day reading was at 0.09.
Analyst Ratings
UBS upgraded Teva Pharmaceutical Industries Limited (NYSE: TEVA) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Sell. The consensus rating for Teva Pharmaceutical Industries Limited (TEVA) among analysts is Hold. According to current brokerage recommendations, 2 brokerage firms advise that investors sell TEVA, while 8 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 3 others rate it as a “buy”.
